Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics PLC grows in Europe and targets US

Revenue in the six months to December 31 rose 12% to £31.5mln
Allergy Therapeutics PLC grows in Europe and targets US
Allergy Therapeutics hopes to expand vaccine business in the US

Allergy Therapeutics PLC (LON:AGY) reported higher revenues and said it had relaunched plans to enter the US market in 2019.

The allergy vaccine specialist said revenue in the six months to December 31 rose 12% to £31.5mln as its share of all major markets increased.

It started a US phase II study for its GrassMatampl product in December and said it was on track for data read-out in the second half of this year.

The group is also expecting the results of its PQ Birch204 Phase II study, for which patient enrolment is complete, in the second half.

It has restarted clinical development plans, aiming to enter the US market following Food & Drug Administration approval in 2019, thereby becoming the first company to launch a subcutaneous vaccine in the seasonal segment of the US allergic rhinitis market.

Chief executive Manuel Llobet said the company's US commercialisation strategy was where significant growth potential lies and its strengthened balance sheet left it well-placed to build a strong allergy business.

"The first half of this year has seen continued momentum with our product sales continuing to outperform the market with further market share gains across Europe," he said.

"Our business is gaining significant scale and momentum in Europe through both organic and acquisitive growth.

"We expect this to continue as we further invest in our commercial infrastructure and prepare to take our products over to the US."

Phil-Waller.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Related Articles

Blood test
Tue
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
Astrazeneca1_5704c41deea83.jpg
April 06 2016
Researchers administered Atu027 to patients with pancreatic cancer, one of the hardest strains of the disease to treat.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.